Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Date:1/7/2008

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) with safety and

tolerability comparable to placebo -

- Conference Call Scheduled for 4:00PM ET Today -

PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. Eighty-five (85%) of patients receiving R7128 1500mg and Pegasys plus Copegus achieved undetectable HCV RNA levels following 4 weeks of treatment with safety and tolerability comparable to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

Dr. Michelle Berrey, Pharmasset's Chief Medical Officer, stated "R7128, in combination with Pegasys plus Copegus, has shown that nucleoside polymerase inhibitors can demonstrate Rapid Virologic Response (RVR) percentages that are similar to protease inhibitors with an acceptable short-term clinical safety profile. This study also suggests that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care that is not found with other classes of HCV inhibitors. The addition of R7128 at both dose levels to the current standard of care has demonstrated a greater percentage of RVR compared to the standa
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
(Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review ... guide on what to do to eliminate the root ... in its review that readers can easily learn what foods ... kidney health. Vkool also informs in its Kidney Disease Solution ... kidney functions naturally. The book consists of a collection of ...
(Date:7/13/2014)... Celebrity fitness trainer and former World ... partnership with Aqua Health Labs for their flagship product ... . The collaboration was recently announced live on ESPN ... , actor, model, and a two time World Super ... he has prepared stars including Demi Moore, Hilary Swank ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the ... http://www.HealthYourself101.com will expand people’s understanding of the causes, ... set out to provide a health education platform on this ... we say it? – entertaining to dig into and learn ... the remote learner – the solitary individual signing on from ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... (OTC Bulletin Board: PLCSF) announced today that it expects to ... fourth quarter and year ended December 31, 2008 before the ... to host a conference call to discuss those results at ... be joined via telephone by dialing (866) 356-3377 or (617) ...
... Living Life as Fully as Possible , ALEXANDRIA, Va., ... Organization wants all people to know that hospice delivers ... family caregivers who are coping with life-limiting illness. A ... Presents Legal Quandary," by Greg Bluestein, 03/02/09) carries a ...
... Known for Her Quest to Raise One Million Dollars for ... JACKSONVILLE, Fla., March 3 At 56, Linda Quirk has ... in just under a year. She began her trek ... 2008 and has since gone on to run the Great ...
... Inc. (Pink Sheets: SNDY) is pleased to announce that ... (FDA) Level II Baseline Inspection and received a NAI ... for the FDA to periodically perform unannounced inspections for ... FDA validates the Company,s quality system and its strict ...
... nine children, One in ten adults. , One in ... home , 402 people died due to asthma in 2006, ... People with asthma should have a written asthma action plan but ... telling patients what to do if their asthma gets worse. An ...
... disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are ... to cirrhosis and hepatocellular carcinoma. To date, ... in these conditions and no approved therapeutic ... system overexpression plays a central role in ...
Cached Medicine News:Health News:NHPCO Comments on Misleading Quote in Associated Press Article and Provides Helpful Information 2Health News:56-Year-Old Grandmother Heads to Antarctica to Run Her Seventh Worldwide Marathon in Under a Year 2Health News:56-Year-Old Grandmother Heads to Antarctica to Run Her Seventh Worldwide Marathon in Under a Year 3Health News:Solos Endoscopy, Inc. Successfully Completes FDA Inspection 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 3
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Knee High Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate mater and body fluids....
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
... Misys Laboratory is a ... that manages specimen data ... specimen tracking to final ... Laboratory is a multi-module ...
Medicine Products: